3 Discovery of Second Generation Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors of Hiv-1

Progress in Medicinal Chemistry

Volumn 40, Issue C, 2002, Pages 63-105

  Corbett, Jeffrey W ^a   Rodgers, James D ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; QUINAZOLINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; QUINAZOLINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036987892     PISSN: 00796468     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6468(08)70082-1     Document Type: Article

References (72)

1. The White House, Office of the Press Secretary: A National Security Strategy for a New Century, January 5, 2000.
2. Kilby J.M., and Saag M.S. In: Powderly W.G. (Ed). Manual of HIV Therapeutics (1997), Lippincott-Raven, New York 1
3. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Nature 373 (1995) 123-126
4. Levy J.A. Microbiol. Rev. 57 (1993) 183
5. Jonckheere H., Anne J., and De Clercq E. Med. Res. Rev. 20 (2000) 129
6. De Clercq E. J. Med. Chem. 38 (1995) 2491
7. Nusbaum N.J., and Joseph P.E. Cell Biol. 15 (1996) 363
8. Kakuda T.N. Clin. Ther. 22 (2000) 685
9. Moyle G. Drug Saf. 23 (2000) 467
10. Götte M., and Wainberg M.A. Drug Resist. Updates 3 (2000) 30
11. Information obtained from package inserts for indinavir (taken without food), ritonavir (taken with food to increase absorption), saquinavir (taken with food to increase absorption).
12. Information on adverse events can be found in the package inserts or on the internet at http://www.aidsmeds.com/lessons/Drug_Chart.htm.
13. Katlama C. Int. J. Clin. Pract., Suppl. 103 (1999) 16
14. Drake S.M. J. Antimkrob. Chemother. 45 (2000) 417
15. Pedersen O.S., and Pedersen E.B. Synthesis 4 (2000) 479
16. Hajós Q., Riedl Z., Molnár J., and Szabó D. Drugs of the Future 25 (2000) 47
17. De Clercq E. Antiviral Res. 38 (1998) 153
18. Sarafianos S.G., Das K., Ding J., Hsiou Y., Hughes S.H., and Arnold E. In: Bently P.H., and O'Hanlon P.J. (Eds). Anti-Infectives (1997), The Royal Society of Chemistry, Cambridge 328-334
19. Artico M. Il Farmaco 51 (1996) 305
20. Crowe S. Adv. Exp. Med. Biol. 458 (1999) 183
21. Williams T.M., Ciccarone T.M., MacTough S.C., Rooney C.S., Balani S.K., Condra J.H., Emini E.A., Goldman M.E., Greenlee W.J., Kaufman L.R., O'Brien J.A., Sardana V.V., Schleif W.A., Theoharides A.D., and Anderson P.S. J. Med. Chem. 36 (1993) 1291
22. Young S.D., Amblard M.C., Britcher S.F., Grey V.E., Tran L.O., Lumma W.C., Huff J.R., Schleif W.A., Emini E.E., O'Brien J.A., and Pettibone D.J. Bioorg. Med. Chem. Lett. 5 (1995) 491
23. Britcher, S. F., Lumma W. C., Young, S. D., Grey, V. E., Tran, L. O. GB-02282808, 1995.
24. Saari W.S., Hoffman J.M., Wai J.S., Fisher T.E., Rooney C.S., Smith A.M., Thomas C.M., Goldman M.E., O'Brien J.A., Nunberg J.H., Quintero J.C., Schleif W.A., Emini E.A., Stern A.M., and Anderson P.S. J. Med. Chem. 34 (1991) 2922
25. Goldman M.E., Nunberg J.H., O'Brien J.A., Quintero J.C., Schleif W.A., Freund K.F., Gaul S.L., Saari W.S., Wai J.S., Hoffman J.M., Anderson P.S., Hupe D.J., Emini E.A., and Stern A.M. Proc. Natl. Acad. Sci. USA 88 (1991) 6863
26. Hoffman J.M., Wai J.S., Thomas C.M., Levin R.B., O'Brien J.A., and Goldman M.E. J. Med. Chem. 35 (1992) 3784
27. Carrol S.S., Olsen D.B., Bennett C.D., Gotlib L., Graham D.J., Condra J.H., Stem A.M., Shafer J.A., and Kuo L.C. J. Biol. Chem. 268 (1993) 276
28. Wai J.S., Williams D.L., Bamberger T.M., Fisher T.E., Hoffman J.M., Hudcosky R.J., MacTough S.C., Rooney C.S., Saari W.S., Thomas C.M., Goldman M.E., O'Brien J.A., Emini E.A., Nunberg J.H., Quintero J.C., Schleif W.A., and Anderson P.S. J. Med. Chem. 36 (1993) 249
29. Goldman M.E. In: Adams J., and Merluzzi V.J. (Eds). The Search for Antiviral Drugs - Case Histories from Concept to Clininc (1993), Birkhuser, Boston 105-127
30. Schooley R.T., Campbell T.B., Kuritzkes D.R., Blaschke T., Stein D.S., Rosandich M.E., Phair J., Pottage J.C., Messari F., Collier A., and Kahn J. J. Acquired Immune Deficiency Syndromes Human Retrovirology 12 (1996) 363
31. Laskin O.L., Duponr A.G., Buntinx A., Schoors D., De Pre M., Van Hecken A., Yen K.C., Woolf E., Eisenhandler R., De Smet M., Patterson P., De Lepeleire I., and De Schepper P.J. Antimicroh. Agents Chemother. 31 (1991) 215
32. Staszewski S., Massari F.E., Kober A., Gohler R., Durr S., Anderson K.W., Schneider C.L., Waterbury J.A., Bakshi K.K., Taylor V.I., Hildebrand C.S., Kreisl C., Hoffstedt B., Schleif W.A., von Briesen H., Rübsamen-Waigmann H., Calandra G.B., Ryan J.L., Stille W., Emini E.A., and Byrnes V.W. J. Infectious Diseases 171 (1995) 1159
33. Davey R., Laskin O., Decker M., O'Neill D., Haneiwich S., Metcalf J., Polis M., Kovacs J., Davis S., Mauer M., Yoder C., Patterson P., Justice S., Yeh K.C., Woolf E., Au T., and Lane H.C. Antimicrob. Agents Chemother. 31 (1991) 215
34. Tucker T.J., Lyle T.A., Wiscount C.M., Britcher S.F., Young S.D., Sanders W.M., Lumma W.C., Goldman M.E., O'Brien J.A., Ball R.G., Homnick C.F., Schleif W.A., Emini E.A., Huff J.R., and Anderson P.S. J. Med. Chem. 37 (1994) 2437
35. Britcher, S. F., Lumma, W. C., Goldman, M. E., Lyle, T. A., Huff, J. R., Payne, L. S., Quesada, M. L., Young, S. D., Sanders, W. M., Sanderson, P. E., Tucker, T. J. EP-00530994, 1993.
36. Houpis I.N., Molina A., Douglas A.W., Xavier L., Lynch J., Volante R.P., and Reider P.J. Tetrahedron Lett. 35 (1994) 6811
37. Huffman M.A., Yasuda N., DeCamp A.E., and Grabowski E.J.J. J. Med. Chem. 60 (1995) 1590
38. Huffmari, M. A., Yasuda, N., DeCamp, A. E., Grabowski, E. J. J. WO 9513273, 1995.
39. Britcher, S. F., Goldman, M. E., Huff, J. R., Lumma, W. C., Lyle, T. A., Payne, L. S., Quesda, M. L., Sanders, W. M., Sanderson, P. E., Tucker, T. J., Young, S. D. WO 9304047, 1992.
40. Britcher, S. F., Goldman, M. E., Huff, J. R., Lumma, W. C., Lyle, T. A., Payne, L. S., Quesda, M. L., Sanders, W. M., Sanderson, P. E., Tucker, T. J., Young, S. D. EP 530994, 1992.
41. Lyle, T. A., Tucker, T. J., Wiscount, C. M. WO 9512583, 1995.
42. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Carrol S.S., Pettibone D.J., O'Brien J.A., Ball R.G., Balani S.K., Lin J.H., Chen I., Schleif W.A., Sardana V.V., Long W.J., Byrnes V.W., and Emini E.A. Antimicroh. Agents Chemother. 39 (1995) 2602
43. Young, S. D., Britcher, S. F., Payne, L. S., Tran, L. O., Lumma, W. C. US 5,519,021, 1996.
44. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skies D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., and Ruiz N.M. New. Engl. J. Med. 341 (1999) 1865
45. Bacheler, L., Weislow, O., Snyder, S., Hanna, G., D'Aquila, R. and the SUSTIVA Resistance Study Team. Abstract presented at the 12th World AIDS Conference, Geneva, Switzerland, June 29-July 3, 1998.
46. Bacheler L.T. Drug Resist. Updates 2 (1999) 56-67
47. Bacheler, L. T., Cordova, B., Hanna, G., D'Aquilla, R. D., Hertogs, K., Larder, B. Abstract 322. 37th Annual Meeting of the Infectious Deseases Society of America, Philadelphia, PA, November 18-21, 1999.
48. Bacheler, L. T., Baker, D., Paul, M., Jeffrey, S., Abremski, K. Abstract 2200. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, 1999.
49. Hoetelmans R.M.W. Antiviral Ther. 4 (1999) 29
50. Patel M., Ko S.S., McHugh Jr. R.J., Markwalder J.A., Srivastava A.S., Cordova B.C., Klabe R.M., Erickson-Viitanen S., Trainor G.L., and Seitz S.P. Bioorg. Med. Chem. Lett. 9 (1999) 2805
51. 12-18
52. Bacheler L.T., Paul M., Jadhav P.K., and Otto Miller M. J. Antiviral Chem. Chemother. 5 (1994) 111
53. The biological activity presented for efavirenz is that of the single enantiomer and, unless reported otherwise, the activity reported for all other compounds is that of the racemate.
54. Patel M., McHugh Jr. R.J., Cordova R.M., Erickson-Viitanen S., Trainor G.L., and Ko S.S. Bioorg. Med. Chem. Lett. 9 (1999) 3221
55. Cocuzza, A. J., Chidester, D. R., Cordova, B. C., Erickson-Viitanen, S., Trainor, G. L., Ko, S. S. To be submitted to Bioorg. Med. Chem. Lett.
56. Corbett J.W., Ko S.S., Rodgers J.D., Gearhart L.A., Magnus N.A., Bacheler L.T., Diamond S., Jeffrey S., Klabe R.M., Cordova B.C., Garber S., Logue K., Trainor G.L., Anderson P.S., and Erickson-Viitanen S.K. J. Med. Chem. 43 (2000) 2019
57. The racemates contain only 50% of the active enantiomer, and the incorrect enantiomers (the R-isomer) are essentially inactive in the biological assays. Therefore, the activity of the single enantiomers would be expected to be approximately one-half that of the racemic values.
58. Bacheler L.T. Drug Resist. Updates 2 (1999) 56-67
59. Copeland R.A. J. Pharm. Sci. 89 (2000) 1000
60. Corbett J.W., Gearhart L.A., Ko S.S., Rodgers J.D., Cordova B.C., Klabe R.M., and Erickson-Viitanen S.K. Bioorg. Med. Chem. Lett. 10 (2000) 193
61. Buckheit Jr. R.W., Fliakas-Boltz V., Decker W.D., Roberson J.L., Pyle C.A., White E.L., Bowdon B.J., McMahon J.B., Boyd M.R., Bader J.P., Nickell D.G., Barth H., and Antonucci T.K. Antiviral Res. 25 (1994) 43
62. Wright J.B. J. Org. Chem. 30 (1965) 3960
63. Magnus N.A., Confalone P.N., and Storace L. Tetrahedron Lett. 41 (2000) 3015
64. Katritzky A.R., Pilarski B., and Urogdi L. Synthesis 949 (1989)
65. Parson A.F., and Pettifer R.M. J. Chem. Soc. Perkin Trans 1 4 (1998) 651
66. Rodney Parsons of Process Research, DuPont Pharmaceuticals Company, discovered the experimental conditions used to install a PMB-group onto 60.
67. Kukla M.J., Breslin H.J., Pauwels R., Fedde C.L., Miranda M., Scott M.K., Sherrill R.G., Raeymaekers A., Van Gelder J., Andries K., Janssen M.A.C., De Clerq E.D., and Janssen P.A. J. Med. Chem. 34 (1991) 746
68. Kukla M.J., Breslin H.J., Diamond C.J., Grous P.P., Ho C.Y., Miranda Milton Rodgers J.D., Sherrill R.G., De Clercq E., Pauwels R., Andries K., Moens L.J., Janssen M.A.C., and Janssen P.A.J. J. Med. Chem. 34 (1991) 3187
69. Bell F.W., Cantrell A.S., Hoegberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., Kinnick M.D., Lind P., Morin Jr. J.M., Noréen R., Öberg B., Palkowitz J.A., Parrish C.A., Pranc P., Sahlberg C., Ternansky R.J., Vasileff R.T., Vrang L., West S.J., Zhang H., and Zhou X.-X. J. Med. Chem. 38 (1995) 4929
70. Cantrell A.S., Engelhardt P., Hoegberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., Kangasmetsae J., Kinnick M.D., Lind P., Morin Jr. J.M., Muesing M.A., Noreén R., Öberg B., Pranc P., Sahlberg C., Ternansky R.J., Vasileff R.T., Vrang L., West S.J., and Zhang H. J. Med. Chem. 39 (1996) 4261
71. Mike, W. et al. 6th Conference on Retrovirus and Opportunistic Infections.
72. Ring, N., Nusrat, R., Lazzarin, A., Arasteh, K., Goebel, F. P., Audagnotto, S., Rachlis, A., Arribas, J. R., Ploughman, L., Fiske, W., Labriola, D., Levy, R., Echols, R., 9th Conference on Retrovirus and Opportunistic Infections; February 24-28, 2002.